+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Low-dose colchicine prevents sympathetic denervation after myocardial ischemia-reperfusion: a new potential protective mechanism


      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.



          To evaluate the impact of colchicine on sympathetic denervation after acute myocardial infarction (AMI).

          Materials & methods:

          Ischemia/Reperfusion was induced in C57BL/6J male mice. Left coronary artery was ligated during 45 min followed by reperfusion. 400 μg/kg of colchicine or the placebo was administrated intraperitoneally 15 min before the reperfusion.


          Colchicine treatment significantly improved heart rate variability index after AMI. Colchicine prevented sympathetic denervation in the remote area (p = 0.04) but not in the scar area (p = 0.70).


          These results suggest promising protective pathway of colchicine after AMI.

          Lay abstract

          This is a preclinical study of acute myocardial infarction in mice treated with colchicine or saline injection. ECG monitoring, immunofluorescence histology and NGF serum level measurement were performed. Here, it is demonstrated that colchicine improves heart rate variability, reduces cardiac denervation. The randomized COLD-MI trial will soon start and include patients. Cardiac denervation will be assessed using nuclear imaging with méta-iodobenzylguanidine (MIBG).

          Most cited references16

          • Record: found
          • Abstract: found
          • Article: not found

          Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction

          Experimental and clinical evidence supports the role of inflammation in atherosclerosis and its complications. Colchicine is an orally administered, potent antiinflammatory medication that is indicated for the treatment of gout and pericarditis.
            • Record: found
            • Abstract: found
            • Article: not found

            Colchicine in Patients with Chronic Coronary Disease

            Evidence from a recent trial has shown that the antiinflammatory effects of colchicine reduce the risk of cardiovascular events in patients with recent myocardial infarction, but evidence of such a risk reduction in patients with chronic coronary disease is limited.
              • Record: found
              • Abstract: found
              • Article: not found

              Cardiac sympathetic denervation assessed with 123-iodine metaiodobenzylguanidine imaging predicts ventricular arrhythmias in implantable cardioverter-defibrillator patients.

              The purpose of this study was to evaluate whether 123-iodine metaiodobenzylguanidine (123-I MIBG) imaging predicts ventricular arrhythmias causing appropriate implantable cardioverter-defibrillator (ICD) therapy (primary end point) and the composite of appropriate ICD therapy or cardiac death (secondary end point). Although cardiac sympathetic denervation is associated with ventricular arrhythmias, limited data are available on the predictive value of sympathetic nerve imaging with 123-I MIBG on the occurrence of arrhythmias. Before ICD implantation, patients underwent 123-I MIBG and myocardial perfusion imaging. Early and late 123-I MIBG (planar and single-photon emission computed tomography [SPECT]) imaging was performed to assess cardiac innervation (heart-to-mediastinum ratio, cardiac washout rate, and 123-I MIBG SPECT defect score). Stress-rest myocardial perfusion imaging was performed to assess myocardial infarction and perfusion abnormalities (perfusion defect scores). During follow-up, appropriate ICD therapy and cardiac death were documented. One-hundred sixteen heart failure patients referred for ICD therapy were enrolled. During a mean follow-up of 23 +/- 15 months, appropriate ICD therapy (primary end point) was documented in 24 (21%) patients and appropriate ICD therapy or cardiac death (secondary end point) in 32 (28%) patients. Late 123-I MIBG SPECT defect score was an independent predictor for both end points. Patients with a large late 123-I MIBG SPECT defect (summed score >26) showed significantly more appropriate ICD therapy (52% vs. 5%, p < 0.01) and appropriate ICD therapy or cardiac death (57% vs. 10%, p < 0.01) than patients with a small defect (summed score

                Author and article information

                Future Sci OA
                Future Sci OA
                Future Science OA
                Future Science Ltd (London, UK )
                23 November 2020
                February 2021
                23 November 2020
                : 7
                : 2
                : FSO656
                [1 ]Department of Cardiology, Montpellier University Hospital, Montpellier, Occitanie, France
                [2 ]University of Montpellier, CNRS, INSERM, CHRU Montpellier, Montpellier, France
                Author notes
                [* ]Author for correspondence: Tel.: +33 0467332501; f-huet@ 123456chu-montpellier.fr

                Authors contributed equally


                Authors contributed equally

                Author information
                © 2020 Fabien Huet

                This work is licensed under the Creative Commons Attribution 4.0 License

                : 29 August 2020
                : 27 October 2020
                : 23 November 2020
                Page count
                Pages: 6
                Short Communication

                colchicine,heart rate variability,myocardial infarction,sympathetic innervation


                Comment on this article